Literature DB >> 2014632

Regulation of HTLV-II gene expression by Rex involves positive and negative cis-acting elements in the 5'long terminal repeat.

A C Black1, I S Chen, S Arrigo, C T Ruland, T Allogiamento, E Chin, J D Rosenblatt.   

Abstract

Regulation of human T-cell leukemia virus type II (HTLV-II) gene expression by the trans-acting viral protein, Rex, is mediated through specific cis-acting sequences in the HTLV-II long terminal repeat (LTR). Augmentation of 5' LTR-linked gene expression by Rex requires two distinct cis-acting elements: one termed the "Rex-responsive element" (RxRE), which allows Rex to overcome the inhibitory effect of a second, termed the "cis-acting repressive sequences" (CRS). The HTLV-II RxRE is located between nt +91 and +317 relative to the cap site in the R/U5 region of the 5'LTR, and the HTLV-II CRS is contained within the RxRE from nt +208 to +317, which is downstream of the splice donor site, in the R/U5 region of the 5' LTR. Deletion of the CRS results in significantly increased cytoplasmic levels of LTR-linked mRNA independent of the presence of Rex. Our results show that Rex acts post-transcriptionally and induces a shift from nucleus to cytoplasm of gag/pol mRNA, the only HTLV-II mRNA that contains both the RxRE and the CRS in the 5' LTR-derived leader sequence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014632     DOI: 10.1016/0042-6822(91)90875-c

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

Review 1.  The human T-cell leukemia virus Rex protein.

Authors:  Ihab Younis; Patrick L Green
Journal:  Front Biosci       Date:  2005-01-01

2.  Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

Authors:  E T Dayton; D A Konings; D M Powell; B A Shapiro; L Butini; J V Maizel; A I Dayton
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  Human T lymphotropic virus type 1 regulatory and accessory gene transcript expression and export are not rex dependent.

Authors:  Min Li; Priya Kannian; Han Yin; Matthew Kesic; Patrick L Green
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

4.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Human T-cell leukemia virus type 2 Rex inhibits pre-mRNA splicing in vitro at an early stage of spliceosome formation.

Authors:  A Bakker; X Li; C T Ruland; D W Stephens; A C Black; J D Rosenblatt
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Specific binding of polypyrimidine tract binding protein and hnRNP A1 to HIV-1 CRS elements.

Authors:  A C Black; J Luo; S Chun; A Bakker; J K Fraser; J D Rosenblatt
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

Review 7.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

8.  Complete nucleotide sequence of the new simian T-lymphotropic virus, STLV-PH969 from a Hamadryas baboon, and unusual features of its long terminal repeat.

Authors:  M Van Brüssel; P Goubau; R Rousseau; J Desmyter; A M Vandamme
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  Polypyrimidine tract-binding protein and heterogeneous nuclear ribonucleoprotein A1 bind to human T-cell leukemia virus type 2 RNA regulatory elements.

Authors:  A C Black; J Luo; C Watanabe; S Chun; A Bakker; J K Fraser; J P Morgan; J D Rosenblatt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.